Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency.

KDM2B is a critical dependency in high-risk medulloblastoma subgroups, with its inhibition suppressing tumor growth by altering chromatin states.

• Why it matters: Understanding how chromatin modifications drive medulloblastoma malignancy can reveal targeted treatment strategies, addressing a key gap in pediatric cancer therapy.
• What they did: The study analyzed chromatin states across medulloblastoma subgroups using multi-modal profiling, identifying KDM2B's aberrant binding at neurodevelopmental gene promoters and its role in tumor growth.
• The result: Targeting KDM2B through genetic or protein degradation methods effectively inhibits tumor proliferation, highlighting its potential as a therapeutic target for high-risk medulloblastoma.